Episurf Medical (NASDAQ: EPIS B) today announces the hiring of Stephen Caswell as Head of Sales, OUS. In this role Stephen will define and execute upon the strategic sales strategy for Episurf's markets outside of the U.S and Canada, working closely with the company's direct sales force and indirect sales partners to accelerate growth. Ensuring that more patients in this under-served segment can benefit from a personalized treatment platform to help reduce pain and maximise function. Stephen will provide an acute focus on driving business acceleration, market development and brand positioning within the international markets.
Stephen has spent the last 7 years with Stryker's Joint Replacement division in various roles covering direct sales, sales management and marketing of Mako Robotics with a focus on both public and private sectors, and most recently held the position of Commercial Director of Strategic Capabilities. In his Mako Robotics role, Stephen focused on marketing of patient specific 3D planning tools for knee replacement procedures.
Prior to Stryker, Stephen practiced as a registered Physiotherapist for 11 years, working in both the U.K public and private sectors. In this segment, he built a company that was later sold. Stephen also has a BSc First Class Hons degree in Physiotherapy, MSc Sports Medicine and an Executive MBA.
"I am incredibly passionate about this under-served patient segment" explains Stephen; "With the combination of detailed 3D planning and damage reporting, patient specific implants and 3D printed patient specific instrumentation, we have a fantastic opportunity to expand the use of this treatment platform to provide improved outcomes for this high functioning patient group". Stephen goes on to explain "when this is combined with the robust clinical data the company have diligently captured, we are well placed to see significant growth across multiple markets".
"I am pleased with having Stephen onboard for this incredibly important assignment. In addition to his strong industry experience, Stephen is highly passionate about helping patients, evidenced by his background in physiotherapy. Episurf is moving from research and development into the commercial phase, and Stephen will play an important role in ensuring that we are taking the next steps", says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 3 December 2021.
(c) 2021 Cision. All rights reserved., source Press Releases - English